- Home
- BDSX vs SCD Comparison
BDSX vs SCD Comparison
Compare BDSX & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDSX
- SCD
- Stock Information
- Founded
- BDSX 2005
- SCD 2003
- Country
- BDSX United States
- SCD United States
- Employees
- BDSX N/A
- SCD N/A
- Industry
- BDSX Precision Instruments
- SCD Trusts Except Educational Religious and Charitable
- Sector
- BDSX Health Care
- SCD Finance
- Exchange
- BDSX Nasdaq
- SCD Nasdaq
- Market Cap
- BDSX 194.9M
- SCD N/A
- IPO Year
- BDSX 2020
- SCD N/A
- Fundamental
- Price
- BDSX $1.51
- SCD $16.71
- Analyst Decision
- BDSX Strong Buy
- SCD
- Analyst Count
- BDSX 4
- SCD 0
- Target Price
- BDSX $3.08
- SCD N/A
- AVG Volume (30 Days)
- BDSX 332.5K
- SCD 62.6K
- Earning Date
- BDSX 11-01-2024
- SCD 01-01-0001
- Dividend Yield
- BDSX N/A
- SCD 9.63%
- EPS Growth
- BDSX N/A
- SCD N/A
- EPS
- BDSX N/A
- SCD N/A
- Revenue
- BDSX $65,562,000.00
- SCD N/A
- Revenue This Year
- BDSX $46.97
- SCD N/A
- Revenue Next Year
- BDSX $30.43
- SCD N/A
- P/E Ratio
- BDSX N/A
- SCD N/A
- Revenue Growth
- BDSX 48.92
- SCD N/A
- 52 Week Low
- BDSX $1.11
- SCD $11.33
- 52 Week High
- BDSX $2.21
- SCD $15.87
- Technical
- Relative Strength Index (RSI)
- BDSX 48.94
- SCD 36.96
- Support Level
- BDSX $1.24
- SCD $17.45
- Resistance Level
- BDSX $1.43
- SCD $17.79
- Average True Range (ATR)
- BDSX 0.10
- SCD 0.37
- MACD
- BDSX 0.01
- SCD -0.14
- Stochastic Oscillator
- BDSX 64.44
- SCD 20.65
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.